The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2020 | ACTIVE trial update: EGFRm NSCLC
Byoung Chul Cho, MD, PhD, Yonsei Cancer Center, Seoul, Korea, discusses updates on the ACTIVE (NCT02824458) multicentered, randomized, double-blind, placebo-controlled phase III trial, comparing the use of apatinib plus gefitinib versus placebo plus gefitinib as first-line treatment for advanced epidermal growth factor receptor-mutant (EGFRm) non-small-cell lung cancer (NSCLC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
